Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept to Hold 2015 Second Quarter Conference Call on August 10
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the quarter ended June 30, 2015 after market close on
View HTML
Toggle Summary Biocept to Hold 2015 Third Quarter Conference Call on November 5
SAN DIEGO , Oct. 29, 2015 /PRNewswire/ --  Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the quarter ended September
View HTML
Toggle Summary Biocept to Hold 2016 First Quarter Conference Call on May 12
SAN DIEGO , May 5, 2016 /PRNewswire/ --  Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company with a commercialized liquid biopsy technology, Target Selector TM , focused on cancer treatment and monitoring, announces that it will release financial results for the three months
View HTML
Toggle Summary Biocept to Hold Business Strategy Conference Call Today
SAN DIEGO --(BUSINESS WIRE)--Jun. 7, 2022-- Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022 , beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer questions.
View HTML
Toggle Summary Biocept to Hold Business Update Conference Call on August 30, 2023
SAN DIEGO --(BUSINESS WIRE)--Aug. 25, 2023-- Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023 , beginning at 4:00 p.m. Eastern time ( 1:00 p.m. Pacific time ) to provide a business update and to answer questions. Participants can pre-register for the conference
View HTML
Toggle Summary Biocept to Host Key Opinion Leader Webinar on April 8 to Discuss its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products
View HTML
Toggle Summary Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Presenters include leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces
View HTML
Toggle Summary Biocept to Host Key Opinion Leader Webinar to Discuss Its CSF Assay for the Diagnosis of Cancer Involving the Central Nervous System
Presenters include Dr. Amir Azadi of Barrow Neurological Institute , Dr. Nicholas Blondin of Yale University and Dr. Priya U. Kumthekar of Northwestern University W ebinar begins tomorrow, April 8 , at 12:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 7, 2021-- Biocept, Inc.
View HTML
Toggle Summary Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
Real-world case studies to be presented by leading neuro-oncologists Dr. Priya U. Kumthekar of Northwestern University and Dr. Seema A. Nagpal of Stanford University SAN DIEGO --(BUSINESS WIRE)--Oct. 14, 2022-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays,
View HTML
Toggle Summary Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
SAN DIEGO , May 20, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W.
View HTML